Given discussion with FDA is still unknown at this stage, I believe FDA approval is not gonna be on the horizon until some time in 2021 unfortunately. Personally I think the MOU with RB is the next big thing for ResApp that's really gonna change its fundamental and it's currently under the radar. Obviously any new European telehealth partners will boost the SP as well.
After some research, I found this interesting article:
https://hbw.pharmaintelligence.informa.com/RS149075/Reckitt-Invests-In-AI-Symptom-Checker-To-Unlock-SelfCare It seems like RB has invested in self-care digital health sector and Your.Md is their first step. I imagine their partnership with ResAppDx is a similar strategic MOU and developing an app like Your.Md where consumers can use it to identify different respiratory conditions and provide recommendednext steps. I believe this direct to consumer approach has the largest market size and the most effect market penetration and the revenue stream will be much bigger than telehealth. We should hopefully hear an update about this by the end of the year.
Below is the info from ResApp's investor presentation back in April this year:
What's everyone thought on this?
GLTAH and DYOR.
RAP Price at posting:
14.5¢ Sentiment: Hold Disclosure: Held
